Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children.

Literature DB >> 32346068

Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children.

Jing Pan¹, Yue Tan², Biping Deng³, Chunrong Tong⁴, Lin Hua⁵, Zhuojun Ling⁴, Weiliang Song⁴, Jinlong Xu⁴, Jiajia Duan⁴, Zelin Wang⁴, Huilin Guo⁶, Xinjian Yu⁶, Alex H Chang⁷, Qinlong Zheng⁸, Xiaoming Feng^9,10.

Abstract

Entities: Gene Species

Mesh：

Substances：

Year: 2020 PMID： 32346068 DOI： 10.1038/s41375-020-0831-z

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

Review 1. Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.

Authors: Zhiyu Liu; Yang Li; Ce Shi
Journal: Int J Hematol Date: 2021-01-27 Impact factor: 2.490

2. Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL.

Authors: Biping Deng; Jing Pan; Zhaoli Liu; Shuangyou Liu; Yunlong Chen; Xiaomin Qu; Yu'e Zhang; Yuehui Lin; Yanlei Zhang; Xinjian Yu; Zhongxin Zhang; Xuansha Niu; Rong Luan; Ming Ma; Xiaomei Li; Tingting Liu; Xi'ai Wu; Huan Niu; Alex H Chang; Chunrong Tong
Journal: Mol Ther Methods Clin Dev Date: 2021-10-27 Impact factor: 6.698

Review 3. Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?

Authors: Jochen Buechner; Ignazio Caruana; Annette Künkele; Susana Rives; Kim Vettenranta; Peter Bader; Christina Peters; André Baruchel; Friso G Calkoen
Journal: Front Pediatr Date: 2022-01-25 Impact factor: 3.418

4. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.

Authors: Jia Wei; Min Xiao; Zekai Mao; Na Wang; Yang Cao; Yi Xiao; Fankai Meng; Weimin Sun; Ying Wang; Xingcheng Yang; Liting Chen; Yicheng Zhang; Haichuan Zhu; Shangkun Zhang; Tongcun Zhang; Jianfeng Zhou; Liang Huang
Journal: Signal Transduct Target Ther Date: 2022-04-11

Review 5. CAR-NK cells for cancer immunotherapy: from bench to bedside.

Authors: Leisheng Zhang; Yuan Meng; Xiaoming Feng; Zhongchao Han
Journal: Biomark Res Date: 2022-03-18

6. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.

Authors: Linde Dekker; Friso G Calkoen; Yilin Jiang; Hilly Blok; Saskia R Veldkamp; Coco De Koning; Maike Spoon; Rick Admiraal; Peter Hoogerbrugge; Britta Vormoor; H Josef Vormoor; Henk Visscher; Marc Bierings; Marieke Van Der Vlugt; Harm Van Tinteren; A Laura Nijstad; Alwin D R Huitema; Kim C M Van Der Elst; Rob Pieters; Caroline A Lindemans; Stefan Nierkens
Journal: Blood Adv Date: 2022-04-12

7. MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.

Authors: Jiachen Wang; Zhen Shang; Jue Wang; Jinhuan Xu; Weigang Li; Yuqi Guan; Li Yang; Wei Zhang; Kefeng Shen; Meilan Zhang; Jin Wang; Liting Chen; Qinlu Li; Cheng He; Na Wang; Liang Huang; Yi Xiao; Min Xiao; Jianfeng Zhou
Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751